Related Experiment Video
Updated: Dec 13, 2025

06:05
A BW Reporter System for Studying Receptor-Ligand Interactions
Published on: January 7, 2019
8.0K
Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab
Pritha Sharma1, Martin Barnes1, Shaha Nabeel1
1Department of Internal Medicine, Mather Hospital/Northwell Health, Port Jefferson, NY.
JCO Oncology Practice
|July 28, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
351
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
351
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
364
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
364

